Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - A pilot study

European Journal of Vascular and Endovascular Surgery

Volumn 18, Issue 4, 1999, Pages 334-338

  Shoab, S S ^a,b   Scurr, J H ^a   Coleridge Smith, P D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Chronic venous disease; Flavonoid; Vascular endothelial growth factor

Indexed keywords

DAFLON; FLAVONOID; VASCULOTROPIN;

ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; DIARRHEA; DOPPLER ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAINTNESS; HEADACHE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN MANIFESTATION; VEIN DISEASE;

EID: 0033213858     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejvs.1999.0890     Document Type: Article

References (16)

1. Saharay M, Shields DA, Porter JB, Scurr JH, Coleridge-Smith PD. Leucocyte activity in the microcirculation of the leg in patients with chronic venous disease. J Vasc Surg. 26:1997;265-273.
2. Leu HJ. Aktuelles Konzept der Entstehung trophischer HautÍläsionen bei der chronisch-venösen Insuffizienz aus morphologischer Sicht. Wiener Medizinische Wochenschrift. 144:1994;199-200.
3. Falanga V. Venous ulceration. J DermSurg Oncology. 19:1993;764-771.
4. Leung DW, Cahianes G, Kuang W-J, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
5. Senger DR, Van de Water L, Brown LF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12:1993;303-324.
6. Brauchle M, Funk JO, Kind P, Werner S. Ultraviolet B and H202 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem. 271:1996;21793-21797.
7. Shoab SS, Scurr JH, Coleridge-Smith PD. Increased plasma vascular endothelial growth factor among patients with chronic venous disease. J Vasc Surg. 28:1998;535-540.
8. Porter JM, Moneta GL. Reporting standards in venous disease: An update. J Vasc Surg. 21:1995;635-645.
9. Shields DA, Andaz SK, Sarin S, Scurr JH, Coleridge-Smith PD. Neutrophil activation in experimental ambulatory venous hypertension. Phlebology. 9:1994;119-124.
10. Porter JM, Moneta GL. Reporting standards in venous disease: An update. J Vasc Surg. 21:1995;635-645.
11. Gilly R, Pillion G, Frileux C. Evaluation of a new micronised flavonoid fraction (S5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: A double-blind placebo controlled study. Phlebology. 9:1994;67-70.
12. Shoab SS, Scurr JH, Coleridge-Smith PD. Scripta Phlebologica. 6:1998;55-57.
13. Burnand KG, Whimster I, Naidoo A, Browse NL. Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipoÍdermatosclerosis and venous ulceration. Br Med J. 285:1982;1071-1072.
14. Koch AE, Harlow LA, Haines GK. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol. 152:1994;4149-4156.
15. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56:1996;4032-4039.
16. Joseph IB, Vukanovic J, Isaacs JT. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res. 56:1996;3404-3408.